+86-28-82633987
Product name: Camellianin A
Synonym name:
Catalogue No.: BP3609
Cas No.: 109232-77-1
Formula: C29H32O15
Mol Weight: 620.56
Botanical Source:
Physical Description:
Type of Compound: Flavonoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
The product could be supplied from milligrams to grams. Inquire for bulk scale.
We provide solution to improve the water-solubility of compounds, thereby facilitating the variety of activity tests and clinic uses.
For Reference Standard and R&D, Not for Human Use Directly.
HPLC of Camellianin A
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
235.0400
.0723
.0400
2.7533
.3991
.1120
Low
77.6090
4.7086
Yes
No
No
No
No
No
0.6
Yes
Yes
Yes
Yes
Natural products, as important resources for drug development, attract much attention due to their structural diversity and biological activity. Flavonoids, as a major class of natural products, are widely found in plants and possess various biological activities including antioxidant, anti-inflammatory, anti-cancer, and cardiovascular protection. Camellianin A is a species derived from the Camellianin family plant A. The main flavonoid compounds isolated from nitida leaves have recently become a research hotspot due to their remarkable anticancer activity and inhibition of angiotensin-converting enzyme (ACE). This paper will systematically review the chemical structure and physicochemical properties of Shanchening A, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, and explore its clinical application prospects and future development directions, aiming to provide scientific basis and reference for drug development of this natural product.
The chemical name of Camellianin A is Camellianin A, CAS number 109232-77-1, and it belongs to the flavonoid class, with a molecular weight of 620.56. Its molecular structure features include a typical flavonoid backbone, connecting multiple hydroxyl and sugar groups, giving it high polarity. In terms of physicochemical properties, the LogP value of Shanchening A is 0.0723, indicating low lipid solubility and good water solubility (solubility about 2.7533), which is consistent with the presence of multiple hydrophilic groups. Its topological pole surface area (TPSA) is 235.04 Ų, indicating that the molecule possesses strong polarity and hydrogen bond donor/acceptor capacity, which significantly affects its bioactivity and pharmacokinetic properties. Additionally, Shanchening A has low blood-brain barrier permeability, with negative results in hERG channel inhibition tests and a 0.6 score in Ames-induced mutagenic tests, indicating good safety and low toxicity risk.
Camellia A is mainly found in Camelliaceae plants A. In the leaves of nitida. A. nitida is distributed in southern China and parts of Southeast Asia, and is widely used as a traditional herbal and tea ingredient. The leaves are rich in flavonoids, with Camellia A being one of the main components.
Common methods for extracting Shanchening A include solvent extraction, column chromatography separation, and high-performance liquid chromatography (HPLC) purification. Ethanol or methanol is generally used as extraction solvents, and ultrasound-assisted extraction is used to improve efficiency. After concentration, liquid-liquid distribution, and silica gel column chromatography separation, the extract is purified by reversed-phase HPLC to obtain high-purity Shanchening A. In recent years, supercritical CO₂ extraction and membrane separation technologies have also been attempted to extract this compound, aiming to improve yield and purity, reduce solvent residues, and environmental impact.
Shanchening A exhibits significant anti-proliferative effects across various tumor cell lines. In vitro studies have shown that Shanchening A can effectively inhibit the proliferation of human liver cancer cells (Hep G2) and breast cancer cells (MCF-7), with a dose-dependent inhibitory effect. Cell cycle analysis showed that Shanhany A induces tumor cell stasis during the G0/G1 phase, blocking the progression of the cell cycle and thereby inhibiting cell division. This mechanism suggests that Shanchening A may exert anti-cancer effects by regulating cell cycle-related protein expression and disrupting cell cycle regulatory networks.
Additionally, some studies report that Shanchening A can induce tumor cell apoptosis, regulate the expression of apoptosis-related proteins such as Bcl-2 family members and caspase enzymes, and enhance cell suicide signaling. Its antioxidant properties may also inhibit tumor cell growth and metastasis by reducing oxidative stress.
Shanchening A inhibits angiotensin-converting enzymes, suggesting its potential application value in regulating blood pressure and protecting cardiovascular health. ACE is a key enzyme in angiotensin II production, involved in blood pressure regulation and water-salt metabolism. Shanchening A inhibits ACE activity and lowers angiotensin II levels, helping to dilate blood vessels, lower blood pressure, and prevent hypertension and related cardiovascular diseases.
In vitro enzyme activity tests showed that Shanchening A had a significant inhibitory effect on ACE without obvious toxic side effects. Its polyhydroxyl structure may inhibit enzyme activity by forming hydrogen bonds and hydrophobic interactions with ACE active sites.
The biological activity of Shanchening A is mainly achieved through regulation of the cell cycle and enzyme activity. Regarding anticancer mechanisms, Shanchening A induces tumor cell G0/G1 phase stasis, which may involve downregulation of Cyclin D1, cyclin-dependent kinase 4/6 (CDK4/6), and upregulation of cell cycle inhibitors p21 and p27. Additionally, Shanchening A can activate the p53 signaling pathway, promoting cell cycle arrest and apoptosis.
In terms of anti-ACE activity, Shanchening A competitively binds to ACE active sites, blocking the conversion of angiotensin I to angiotensin II, inhibiting vasoconstriction and sodium-water retention, thereby exerting antihypertensive effects. Molecular docking and kinetic simulation studies support its high affinity for binding to ACE active centers.
Additionally, the antioxidant activity of Shanchening A reduces oxidative stress damage by scavenging free radicals, inhibiting lipid peroxidation, and enhancing endogenous antioxidant enzyme activity, thereby indirectly participating in cancer prevention and cardiovascular protection.
The druggability parameters of Shanchening A indicate that it has certain development potential. Although the molecular weight of 620.56 is slightly above the 500 recommended by Lipinski's rules, its LogP value is extremely low (0.0723), indicating good water solubility and conducive oral absorption. The TPSA value is 235.04, and its higher polarity may limit its cell membrane permeability, especially the lower blood-brain barrier penetration, reducing the risk of central nervous system side effects.
In terms of safety, the hERG ion channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames trial scored 0.6, indicating low mutagenicity and good safety.
Pharmacokinetic research is still in its early stages. The characteristics of absorption, distribution, metabolism, and excretion (ADME) in the body require further clarification. Given its high polarity and molecular weight, Shanchening A may have low oral bioavailability, requiring pharmaceutical formulation improvements or structural modifications to enhance its pharmacokinetic performance.
As a natural flavonoid compound, Shanchening A shows broad application prospects in tumor treatment and cardiovascular disease prevention and treatment due to its anti-cancer and anti-ACE activities. Its dual effect of inducing tumor cell cycle blockade and inhibiting ACE activity makes it possible to develop multi-target drugs.
Future research should focus on the following aspects:
In-depth mechanism research: Through genomics, proteomics, and metabolomics techniques, we comprehensively analyze the action network and molecular targets of Shanchening A, revealing its molecular mechanisms for anticancer and cardiovascular protection.
Pharmacokinetic and toxicological evaluation: Systematic in vivo pharmacokinetic studies are conducted to clarify absorption, distribution, metabolism, and excretion characteristics, assess long-term toxicity and safety, and provide a basis for clinical application.
Structural optimization and formulation development: Targeting its high polarity and molecular weight, structural modification and novel drug carrier system design are carried out to improve bioavailability and targetability.
Preclinical and clinical research: Conducting animal models to verify efficacy and safety, gradually advancing clinical trials to evaluate therapeutic potential in oncology and cardiovascular diseases.
Combination Drug Strategy: Explore the combined use of Shanchening A with existing anticancer or antihypertensive drugs, evaluating synergistic effects and attenuating and enhancing efficacy.
Shanchening A, derived from A. The main flavonoid natural products of nitida leaves, with their unique chemical structure and remarkable biological activity, have become important subjects for pharmacological research of natural products. Its anticancer and anti-ACE activities offer new ideas for developing novel anti-tumor and cardiovascular disease drugs. Although current research on its pharmacological mechanisms and pharmacokinetics remains limited, existing data indicate its promising safety and drug potential. In the future, through multidisciplinary collaboration and technological innovation, Shancha Ning A is expected to move from laboratory research to clinical application, benefiting patients and advancing the field of natural product drug development.
Shenshuai
Wenjing
Hedandan
